Skip to main content

Table 3 Inflammasome interventions in tumor-related clinical trials

From: Involvement of inflammasomes in tumor microenvironment and tumor therapies

Interventions related to inflammasomes

Diseases

Stage of development

Comments

NCT numbers

Glycyrrhizin

Lung cancer

I/II (completed)

NLRP3 inhibitor

NCT02449122

Liver cancer

I/II (completed)

NLRP3 inhibitor

NCT02449109

ACT001

Glioblastoma

I/II (recruiting)

NLRP3 inhibitor

NCT05053880

Andrographolides

Colon cancer

II (terminated)

NLRP3/AIM2 inhibitor

NCT01993472

Methylene Blue

Colon cancer

III (completed)

broad-spectrum inflammasome inhibitor

NCT01694966

Methylene blue

Breast cancer

Not Applicable

broad-spectrum inflammasome inhibitor

NCT02084784

BMS-986299

Advanced cancer

I (terminated)

NLRP3 activator

NCT03444753

Thalidomide

Prostate cancer

II (completed)

caspase-1 inhibitor

NCT00400517

Thalidomide

Multiple myeloma

III (completed)

caspase-1 inhibitor

NCT01296503

Canakinumab

Lung cancer

III (completed)

IL-1β inhibitor

NCT01327846

Canakinumab

Lung cancer

III (active, not recruiting)

IL-1β inhibitor

NCT 03,447,769

Canakinumab

Lung cancer

II (recruiting)

IL-1β inhibitor

NCT04905316

Canakinumab

Lung cancer

III (active, not recruiting)

IL-1β inhibitor

NCT03631199

Canakinumab

Lung cancer

II (completed)

IL-1β inhibitor

NCT 03,968,419

Canakinumab

Lung cancer

II (recruiting)

IL-1β inhibitor

NCT04789681

Canakinumab

Lung cancer

III (completed)

IL-1β inhibitor

NCT03626545

Canakinumab

Lung cancer

I (terminated)

IL-1β inhibitor

NCT03064854

Canakinumab

Lung cancer, breast cancer, colon cancer

I (completed)

IL-1β inhibitor

NCT02900664

Canakinumab

Pancreatic cancer

I (active, not recruiting)

IL-1β inhibitor

NCT04581343

Canakinumab

Pancreatic cancer

III (recruiting)

IL-1β inhibitor

NCT04229004

Canakinumab

Breast cancer

I (active, not recruiting)

IL-1β inhibitor

NCT03742349

Canakinumab

Myelodysplastic syndromes and chronic myelomonocytic leukemia

II (recruiting)

IL-1β inhibitor

NCT04239157

Canakinumab

Myelodysplastic syndromes

II (recruiting)

IL-1β inhibitor

NCT05237713

Canakinumab

Myelodysplastic syndromes

I/II (recruiting)

IL-1β inhibitor

NCT04798339

Canakinumab

Myelodysplastic syndromes

I (recruiting)

IL-1β inhibitor

NCT04810611

Canakinumab

Renal cancer

Early Phase 1 (recruiting)

IL-1β inhibitor

NCT04028245

Canakinumab

Melanoma

II (active, not recruiting)

IL-1β inhibitor

NCT03484923

Canakinumab

Clonal cytopenias of unknown significance

II (recruiting)

IL-1β inhibitor

NCT05641831

Gevokizumab

Colon cancer

I (active, not recruiting)

IL-1β inhibitor

NCT03798626

Tadekinig alfa (IL-18BP)

CAR T-cell-related cytokine release syndrome

Early Phase 1 (recruiting)

IL-18 inhibitor

NCT05306080

Xilonix

Colon cancer

III (terminated)

IL-1α inhibitor

NCT01767857

Xilonix

Colon cancer

III (completed)

IL-1α inhibitor

NCT02138422

Xilonix

Pancreatic cancer

I (completed)

IL-1α inhibitor

NCT03207724

Xilonix

Advanced cancer

I (completed)

IL-1α inhibitor

NCT01021072

SB-485232

Ovarian cancer

I (completed)

Recombinant IL-18

NCT00659178

SB-485232

Melanoma

II (completed)

Recombinant IL-18

NCT00107718

SB-485232

Lymphoma

I (completed)

Recombinant IL-18

NCT00500058

SB-485232

Lymphoma

I (completed)

Recombinant IL-18

NCT01768338

SB-485232

Solid tumor

I (completed)

Recombinant IL-18

NCT00085878

SB-485232

Solid tumor and lymphoma

I (completed)

Recombinant IL-18

NCT00085904

ST-067

Solid tumor

I/II (recruiting)

Recombinant IL-18

NCT04787042

huCART19-IL18

Leukemia and lymphoma

I (recruiting)

CAR-T targeting CD19 and expressing IL-18

NCT04684563

Anakinra

Breast cancer

I (completed)

IL-1 receptor inhibitor

NCT01802970

Anakinra

Rectal cancer

I (recruiting)

IL-1 receptor inhibitor

NCT04942626

Anakinra

Colon cancer

II (completed)

IL-1 receptor inhibitor

NCT02090101

Anakinra

Pancreatic cancer

I (unknown)

IL-1 receptor inhibitor

NCT02021422

Anakinra

Pancreatic cancer

Early I (completed)

IL-1 receptor inhibitor

NCT02550327

Anakinra

Pancreatic cancer

II (not yet recruiting)

IL-1 receptor inhibitor

NCT04926467

Anakinra

Prostate cancer

I (active, not recruiting)

IL-1 receptor inhibitor

NCT04227275

Anakinra

Multiple myeloma and plasma cell neoplasm

II (completed)

IL-1 receptor inhibitor

NCT00635154

Anakinra

Multiple myeloma

I/II (active, not recruiting)

IL-1 receptor inhibitor

NCT03430011

Anakinra

Multiple myeloma

II (completed)

IL-1 receptor inhibitor

NCT03233776

Anakinra

Multiple myeloma

II (recruiting)

IL-1 receptor inhibitor

NCT04099901

Anakinra

Myeloma

I (completed)

IL-1 receptor inhibitor

NCT02492750

Anakinra

B-cell lymphoma

II (active, not recruiting)

IL-1 receptor inhibitor

NCT04432506

Anakinra

B-cell lymphoma

II (recruiting)

IL-1 receptor inhibitor

NCT04359784

Anakinra

B-cell lymphoma

II (recruiting)

IL-1 receptor inhibitor

NCT04205838

Anakinra

Lymphoma

II (active, not recruiting)

IL-1 receptor inhibitor

NCT04150913

Anakinra

B-cell lymphoma/leukemia

II (recruiting)

IL-1 receptor inhibitor

NCT04148430

Anakinra

Chronic lymphocytic leukemia

I (unknown)

IL-1 receptor inhibitor

NCT04691765

Anakinra

Solid tumor

I (completed)

IL-1 receptor inhibitor

NCT00072111

Anakinra

Advanced Cancer

I (completed)

IL-1 receptor inhibitor

NCT01624766